AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
AbCellera (Nasdaq: ABCL) announced its participation in the Truist Securities AI Symposium on March 1, 2022, at 8:20 a.m. Pacific Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
A live audio webcast of the panel may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223006146/en/
Inquiries
Media:
Business Development:
Investor Relations:
Source: